Global drugmakers look set for better protection of their legal rights in Russia

2 September 2019

The disputes between manufacturers of original drugs and their Russian rivals may have a new twist in the local market, as the Russian Supreme Court has supported AstraZeneca (LSE: AZN) in its legal fight with Jodas Expoim – a Russian subsidiary of Indian firm Jodas Expoim Pvt Ltd – by the ordering withdrawal of the certificate for its generic copy of Iressa (gefitinib), reports The Pharma Letter’s local correspondent.

In May 2018, Anglo-Swedish pharma major AstraZeneca filed a lawsuit against Jodas Expoim in the Moscow Arbitration Court with a request to protect its patent rights for the anticancer drug Iressa.

Prior to this, Jodas Expoim registered the maximum selling price for generic gefitinib in the Russian State Registry, which was considered by AstraZeneca as a preparation for a full-scale launch of the generic on the market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK